Aerobiotix Supports Updates to AORN’s Sterile Technique Guidelines

Aerobiotix, LLC, a leader in medical air decontamination technology, supports the recent updates to the Association of periOperative Registered Nurses (AORN) Sterile Technique Guidelines. Effective April 18, 2024, these changes emphasize the importance of managing air quality in surgical environments to reduce the risk of Surgical Site Infections (SSIs).

Paul Ciovacco, Vice President of Sales for Aerobiotix

“Aerobiotix is committed to helping healthcare facilities meet these new guidelines: “The latest recommendations from AORN reinforce the essential role of advanced air decontamination systems in today’s operating rooms. Aerobiotix is dedicated to providing technologies like the Illuvia Sense, which meet and exceed these new standards, ensuring safer surgical environments for patients and healthcare professionals.”

Illuvia Sense, an FDA-registered Class II medical device from Aerobiotix, is known for significantly reducing airborne contaminants without interrupting hospital workflows. This system aligns with the new AORN guidelines, which recommend implementing air quality management strategies in environments where surgical and other invasive procedures are performed.

In conjunction with these guideline updates, Aerobiotix is excited to host a Continuing Education (CE) event, “Mastering Modern Sterile Techniques: A Deep Dive into the New AORN Guidelines.” Led by Dr. Hudson Garrett, this webinar is scheduled for May 23, 2024, from 1-2 p.m. (EDT) and will provide attendees with 1.0 hours of CE credits. Dr. Garrett will discuss the significant changes in the guidelines and offer insights on how healthcare professionals can apply these updates in various clinical settings.

Dr. Garrett shared his enthusiasm for the upcoming event: “Continuing programs such as this represent the perfect opportunity for healthcare professionals to apply the evidence-based recommendations from AORN so that every patient and healthcare team member can benefit from their clinical benefit. The time to improve healthcare safety is now, and together, we can raise the bar for healthcare air quality.”

Healthcare professionals, including registered nurses, infection preventionists, and risk managers, are encouraged to register for the webinar to enhance their understanding of the new guidelines and learn about comprehensive air quality management programs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”